Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.24950/rspmi.1204 |
Resumo: | Introduction: SARS-CoV-2 infection is characterized by hyperproduction of pro-inflammatory cytokines that impact the cardiovascular system. In addition, several cardiovascular risk factors, like arterial hypertension, were identified as risk factors for greater disease severity and mortality in these patients. The objective of this study is to evaluate the prevalence of hypertension in patients with COVID-19 and its association with complications, comorbidities and mortality. Methods: Retrospective study of the patients with COVID-19 admitted to Internal Medicine ward between March 2020 and February 2021. Data was collected from the digital clinical file. Logistic regression was applied to clarify the effect of independent variables on mortality. Results: The sample included 1291 patients with COVID-19, a median age of 73 years (IQR: 22) and male gender predominance (n = 701, 54.3%). There were 65.5% (n = 845) of patients with hypertension, 54.9% (n = 709) dyslipidemia and about a third had diabetes mellitus and obesity (31 and 38%, respectively). Comparatively to the non-hypertensive patients, hypertensive group presented with higher prevalence of other cardiovascular risk factors (diabetes mellitus, obesity and dyslipidemia (p <0.001)) and lower functionality and more comorbidities (as calculated by AVDezIS and Charlson modified scores, p<0.001). There was also higher proportion of severe COVID-19 disease (p = 0.003), greater number of patients admitted to intensive care units (p <0.001) and higher in-hospital mortality (p <0.001). Hypertension was not a mortality predictive factor in these patients. Conclusion: In this study, patients with hypertension presented with higher severity of COVID-19 disease, higher prevalence of other cardiovascular risk factors, complications during hospitalization and in-hospital mortality, however, its presence was not a mortality predictive factor. |
id |
RCAP_303b9352dc6f3d396b3f4945880ffd1d |
---|---|
oai_identifier_str |
oai:oai.revista.spmi.pt:article/1204 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Hypertension and COVID-19: Relation with Complications, Comorbidities and MortalityHipertensão Arterial e COVID-19: Avaliação da Relação com Complicações, Comorbilidades e MortalidadeComorbilidadeCOVID-19HipertensãoMortalidade HospitalarSARS-CoV-2ComorbidityCOVID-19Hospital MortalityHypertensionSARS-CoV-2Introduction: SARS-CoV-2 infection is characterized by hyperproduction of pro-inflammatory cytokines that impact the cardiovascular system. In addition, several cardiovascular risk factors, like arterial hypertension, were identified as risk factors for greater disease severity and mortality in these patients. The objective of this study is to evaluate the prevalence of hypertension in patients with COVID-19 and its association with complications, comorbidities and mortality. Methods: Retrospective study of the patients with COVID-19 admitted to Internal Medicine ward between March 2020 and February 2021. Data was collected from the digital clinical file. Logistic regression was applied to clarify the effect of independent variables on mortality. Results: The sample included 1291 patients with COVID-19, a median age of 73 years (IQR: 22) and male gender predominance (n = 701, 54.3%). There were 65.5% (n = 845) of patients with hypertension, 54.9% (n = 709) dyslipidemia and about a third had diabetes mellitus and obesity (31 and 38%, respectively). Comparatively to the non-hypertensive patients, hypertensive group presented with higher prevalence of other cardiovascular risk factors (diabetes mellitus, obesity and dyslipidemia (p <0.001)) and lower functionality and more comorbidities (as calculated by AVDezIS and Charlson modified scores, p<0.001). There was also higher proportion of severe COVID-19 disease (p = 0.003), greater number of patients admitted to intensive care units (p <0.001) and higher in-hospital mortality (p <0.001). Hypertension was not a mortality predictive factor in these patients. Conclusion: In this study, patients with hypertension presented with higher severity of COVID-19 disease, higher prevalence of other cardiovascular risk factors, complications during hospitalization and in-hospital mortality, however, its presence was not a mortality predictive factor.Introdução: A infeção por SARS-CoV-2 caracteriza-se por um estado de sobreprodução de citocinas pró-inflamatórias que podem culminar com atingimento cardiovascular. Além disso, vários fatores de risco cardiovascular, como a hipertensão arterial (HTA), têm sido associados a maior severidade e mortalidade na COVID-19. O objetivo deste estudo é avaliar a prevalência da HTA nos doentes com COVID-19 e a sua associação com complicações, comorbilidades e mortalidade. Métodos: Estudo retrospetivo dos doentes admitidos em enfermaria por COVID-19 entre março de 2020 e fevereiro de 2021. Foi realizada colheita de dados através do processo clínico. Aplicada regressão logística para clarificar o efeito de variáveis independentes na mortalidade. Resultados: Incluíram-se 1291 doentes com COVID-19 internados no período descrito, com mediana de idades de 73 anos (AIQ: 22) e predomínio do sexo masculino (n = 701, 54,3%). Observou-se que 65,5% (n = 845) dos doentes tinham HTA, 54,9% (n = 709) dislipidemia e 31% e 38% tinham diabetes mellitus e obesidade, respetivamente. Comparativamente com os indivíduos sem HTA, o grupo com HTA apresentou maior prevalência de fatores de risco cardiovascular (diabetes, obesidade e dislipidemia, p <0,001) bem como menor grau de funcionalidade e maior carga de doença (respetivamente score de AVDezIs e Charlson modificado, p <0,001). Verificou-se uma maior proporção de doença grave (p = 0,003), maior número admissões em Unidade de Cuidados Intensivos (p <0,001) e maior taxa de mortalidade intra-hospitalar (p <0,001). A presença de HTA não se revelou como preditor de mortalidade nos doentes com COVID-19. Conclusão: Nesta amostra os doentes com HTA apresentaram múltiplos fatores de risco cardiovascular, doença COVID-19 mais grave, mais complicações e mortalidade intra-hospitalares, contudo, a sua presença não foi um fator preditor de mortalidade por COVID-19.Sociedade Portuguesa de Medicina Interna2023-03-03info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.24950/rspmi.1204https://doi.org/10.24950/rspmi.1204Internal Medicine; Vol. 30 No. 1 (2023): Janeiro/Março; 21-26Medicina Interna; Vol. 30 N.º 1 (2023): Janeiro/Março; 21-262183-99800872-671Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spmi.pt/index.php/rpmi/article/view/1204https://revista.spmi.pt/index.php/rpmi/article/view/1204/1167Direitos de Autor (c) 2023 Medicina Internainfo:eu-repo/semantics/openAccessGonçalves Fontoura, Mário GilCampos Cunha, JoãoDias, DianaMachado, FilipeSoares, BrunoRibeiro, Heloísa2023-07-08T06:10:13Zoai:oai.revista.spmi.pt:article/1204Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:48:10.570956Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality Hipertensão Arterial e COVID-19: Avaliação da Relação com Complicações, Comorbilidades e Mortalidade |
title |
Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality |
spellingShingle |
Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality Gonçalves Fontoura, Mário Gil Comorbilidade COVID-19 Hipertensão Mortalidade Hospitalar SARS-CoV-2 Comorbidity COVID-19 Hospital Mortality Hypertension SARS-CoV-2 |
title_short |
Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality |
title_full |
Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality |
title_fullStr |
Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality |
title_full_unstemmed |
Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality |
title_sort |
Hypertension and COVID-19: Relation with Complications, Comorbidities and Mortality |
author |
Gonçalves Fontoura, Mário Gil |
author_facet |
Gonçalves Fontoura, Mário Gil Campos Cunha, João Dias, Diana Machado, Filipe Soares, Bruno Ribeiro, Heloísa |
author_role |
author |
author2 |
Campos Cunha, João Dias, Diana Machado, Filipe Soares, Bruno Ribeiro, Heloísa |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Gonçalves Fontoura, Mário Gil Campos Cunha, João Dias, Diana Machado, Filipe Soares, Bruno Ribeiro, Heloísa |
dc.subject.por.fl_str_mv |
Comorbilidade COVID-19 Hipertensão Mortalidade Hospitalar SARS-CoV-2 Comorbidity COVID-19 Hospital Mortality Hypertension SARS-CoV-2 |
topic |
Comorbilidade COVID-19 Hipertensão Mortalidade Hospitalar SARS-CoV-2 Comorbidity COVID-19 Hospital Mortality Hypertension SARS-CoV-2 |
description |
Introduction: SARS-CoV-2 infection is characterized by hyperproduction of pro-inflammatory cytokines that impact the cardiovascular system. In addition, several cardiovascular risk factors, like arterial hypertension, were identified as risk factors for greater disease severity and mortality in these patients. The objective of this study is to evaluate the prevalence of hypertension in patients with COVID-19 and its association with complications, comorbidities and mortality. Methods: Retrospective study of the patients with COVID-19 admitted to Internal Medicine ward between March 2020 and February 2021. Data was collected from the digital clinical file. Logistic regression was applied to clarify the effect of independent variables on mortality. Results: The sample included 1291 patients with COVID-19, a median age of 73 years (IQR: 22) and male gender predominance (n = 701, 54.3%). There were 65.5% (n = 845) of patients with hypertension, 54.9% (n = 709) dyslipidemia and about a third had diabetes mellitus and obesity (31 and 38%, respectively). Comparatively to the non-hypertensive patients, hypertensive group presented with higher prevalence of other cardiovascular risk factors (diabetes mellitus, obesity and dyslipidemia (p <0.001)) and lower functionality and more comorbidities (as calculated by AVDezIS and Charlson modified scores, p<0.001). There was also higher proportion of severe COVID-19 disease (p = 0.003), greater number of patients admitted to intensive care units (p <0.001) and higher in-hospital mortality (p <0.001). Hypertension was not a mortality predictive factor in these patients. Conclusion: In this study, patients with hypertension presented with higher severity of COVID-19 disease, higher prevalence of other cardiovascular risk factors, complications during hospitalization and in-hospital mortality, however, its presence was not a mortality predictive factor. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-03-03 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.24950/rspmi.1204 https://doi.org/10.24950/rspmi.1204 |
url |
https://doi.org/10.24950/rspmi.1204 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revista.spmi.pt/index.php/rpmi/article/view/1204 https://revista.spmi.pt/index.php/rpmi/article/view/1204/1167 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2023 Medicina Interna info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2023 Medicina Interna |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Medicina Interna |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Medicina Interna |
dc.source.none.fl_str_mv |
Internal Medicine; Vol. 30 No. 1 (2023): Janeiro/Março; 21-26 Medicina Interna; Vol. 30 N.º 1 (2023): Janeiro/Março; 21-26 2183-9980 0872-671X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130952899756032 |